Definitive Contract HT942525CE039
Award Date 9/22/25
Potential Completion Date 12/31/27
Potential Value $3.2M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Fixed Price Level of Effort
Place of Performance
Morrisville, NC, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
44
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase III Action
Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency awarded a $2.23M fixed-price level of effort contract to Inhalon Biopharma, Inc. on September 23, 2024, for the development of IN-007, an inhaled therapeutic treatment targeting pathogens that utilize human ACE2 receptors for viral attachment and entry. The contract, which carries no set-aside designation, is scheduled for completion by December 22, 2026, and will be performed at Inhalon's facilities in Morrisville, North Carolina. The revised statement of work includes...
- Enalare Therapeutics Inc. was awarded a $55.8M cost-plus-fixed-fee definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a component of the Department of Health and Human Services, to develop an agnostic respiratory stimulant as a medical countermeasure for treating respiratory depression. The contract, with an ultimate completion date of September 30, 2028, originated from a Biomedical Advanced Research and Development Authority (BARDA) Broad...
- <p>This is a $225,000.00 Firm Fixed Price Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Windtree Therapeutics, Inc. under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for the development of a "K4L SURFACTANT AEROSOL TO REDUCE INFLUENZA LUNG INJURY" and has an ultimate completion date of December 31, 2016. The contract is designated as a Total Small Business set-aside.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
- The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
- This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
- The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Inimmune Corp, a small business biotechnology company, for the "Discovery of New Small Molecule TLR4 Agonists for the Treatment of Allergic Rhinitis". The $631,425.00 Firm Fixed Price contract has a period of performance from July 31, 2018 to July 31, 2020. Inimmune Corp, which has...
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Air Force Research Laboratory (AFRL) to Glydertech, Incorporated, a self-certified small disadvantaged business. The contract, valued at $1,249,998.00, is for the development of a rapid multiplex detection system for respiratory diseases to protect critical strategic assets. The contract has a completion date of July 21, 2024 and is a firm-fixed-price purchase order. This SBIR Phase II award builds upon...
- This is a $3,007,557.97 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of new platform technologies for viral and therapeutic evolution assays under DARPA's Small Business Innovation Research (SBIR) Program Phase II. The contract has a firm fixed price pricing type and a period of performance through November 2022. Autonomous Therapeutics has also...
- The Defense Health Agency (DHA) awarded a Phase III Small Business Innovation Research (SBIR) Other Transaction Agreement to Ophirex, Inc., a small business pharmaceutical company based in Corte Madera, California, on May 5, 2025. The contract, valued at approximately $60 million with an ultimate completion date of May 4, 2028, supports the continued development of a broad-spectrum snakebite antidote with an oral product formulation. This award represents the conclusion phase of Ophirex's...